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INTRODUCTION
In the early part of the 20th century, several attempts were made to identify and
analyze ions, chemicals and other molecules found in saliva (Kirk, 1903; Michaels,
1901). These efforts served as proof of principle for saliva to become a diagnostic fluid in
the years to follow. Improved technology has made it possible to identify, measure and
monitor the level of ions, chemicals and macromolecules in saliva (Mayhall, 1975;
Mandel and Wotman, 1976). Rapid advances in pharmacology have translated into
precise methods of monitoring saliva to measure drugs and substances of abuse (Edgar,
1992; Beeley, 1991).
The traditional biological samples for the qualitative and quantitative
measurement of most drugs are blood, plasma and urine. Many substances and their
metabolites are present in different concentrations in these media. Blood or plasma
provides an estimate of the current circulating concentration of the analyte of interest.
Urine pennits measurement of the accumulated concentration of analytes since the last
void of the bladder. Even though it has been convincingly demonstrated that for many
drugs, the monitoring of saliva is a real alternative for detennining plasma levels its
adoption has been slow. Saliva lacks "the drama of blood, the sincerity of sweat and the
emotional appeal of tears" (Mandel, 1990). Collection of saliva and gingival crevicular
fluid (GCF) is noninvasive and painless. Therefore, samples can be easily obtained,
stored and analyzed using biochemical and molecular reactions (Malamud, 1992). In
recent years saliva has attracted considerable attention, in particular among people
interested in the determination of drug concentrations, who suggest that saliva might be
substituted for plasma in the areas of pharmacokinetic studies and drug monitoring.
Background
Saliva
Saliva is a complex fluid that is produced by a number of specialized glands that
discharge into the oral cavity of mammals. A small contribution is made by the numerous
small labial, buccal and palatal glands, which line the mouth (Van Dam and Van Loenen,
1978; Vining and McGinley, 1985). The salivary glandular tissue is comprised of
specialized groups of cells called acinar cells arranged as endpieces surrounding a small
central lumen that opens into a narrow intercalated duct. The intercalated duct leads from
the secretory endpieces to the striated ducts, which in tum drain into the excretory ducts,
that join to form a single main excretory duct, which drains into the oral cavity. The
salivary glands are lobulated, the parenchyma consisting ofdiscrete lobules of closely
packed secretory endpieces and intralobular ducts. The lobules are separated by
interlobular connective tissue septae. The secretory endpieces are supported by cells
called myoepithelial cells that are contractile in nature and contain filaments ofactin and
myosin. Since these cells lie within the basal lamina that envelops the endpiece, they are
considered a part of the endpiece. These cells have an important, though indirect role to
play in salivary secretion. They provide support for the endpiece, preventing its distention
during the secretory process, and in special cases, provide a propulsive force to aid in the
expulsion of especially viscous secretions (Young and Van Lennep, 1978).
The parotid glands are serous glands, for their acini contain only serous-secreting
cells, and their secretions are devoid of mucin. The secretory end-pieces of the
submandibular and sublingual glands, on the contrary, contain both serous and mucin-
2
3secreting cells (Dawes, 1966; Davenport, 1977). The viscosity of the submandibular
saliva usually decreases with increasing flow rate since the serous cells have a greater
response to stimulation than the mucin-secreting cells. The sublingual glands contain
predominantly mucin-secreting cells and thus their secretion has a thick, viscous nature
(Vining and McGinley, 1985).
A recent review (Edgar, 1992) states that salivary glands are unique among the
digestive tract glands in that they are under nervous control. Salivary secretion is (a reflex
response) controlled by both parasympathetic and sympathetic secretomotor nerves.
Stimulation of sympathetic fibers to all glands causes vasoconstriction, and in man,
stimulation of the sympathetic trunk in the neck, or injection of epinephrine, causes
secretion by the submandibular but not the parotid glands. Parasympathomimetic drugs
cause high salivary flow rates (Davenport, 1977; Mazariegos et aI, 1984).
An adult produces typically between 500-1500ml of saliva each day (Lentner,
1981). The volume of saliva secreted appears to be entirely a function of the activity of
the secretory endpiece, the ductal system neither adding nor reabsorbing more water
(Young and Van Lennep, 1979). It is a very dilute fluid, consisting of 99% water.
Salivary proteins comprise approximately 200mg/l00ml (Edgar, 1992). Mixed saliva,
which is the most accessible and most frequently used for analysis, contains primarily the
secretions of the submandibular (65%), parotid (23%) and sublingual (4%) glands, the
remaining 8% being produced by the numerous minor salivary glands (Dawes and Wood,
1973; Caddy, 1984). These proportions are a function of the type, intensity and duration
of stimulation. It has been demonstrated that saliva contains various proteins and
glycoproteins (Carlson, 1988), especially proline-rich proteins (PRPs) that account for
4nearly 70% of protein in saliva and are mainly found in parotid saliva (Bennick, 1982).
The presence of other salivary proteins in very low concentrations has made
characterization of these proteins difficult in the past (Ritschel and Thompson, 1983).
Recently, however, technology has advanced sufficiently, that even a small quantity of
saliva or other fluid can be characterized with confidence (Mandel and Wotman, 1976).
Saliva is known play an important role in the oral cavity in various ways. In
addition to assisting in the dilution and clearance of food, the alkaline nature of saliva
acts as a buffer against acids in food and plaque. The functions of salivary proteins were
recognized by Mayhall (1975), and more recently, Edgar (1992). The a-amylase in saliva
initiates digestion of starches, the mucins provide IlLbrication of oral tissues enabling
physiological functions such as speech, mastication and deglutition. In addition, the
PRP's may play an important anti-microbial role along with several other salivary
proteins such as lysozyme, lactoferrin, peroxidases and immunoglobulins such as IgA,
the presence of which has been demonstrated in human saliva (Ellison et aI, 1960;
Tomasi et aI, 1963). The partial or complete absence of saliva has been shown to result in
significant dysfunction, including impaired speech and mastication, increased
susceptibility to infection and inflammation of oral tissues and increased incidence of
dental caries and periodontal diseases (Fox et aI, 1985).
As saliva is essential to the maintenance of oral health, proper digestion and
nutrition, alterations in its composition may provide clues to an individual's susceptibility
to various types oforal infections and also help serve as a marker in the progression of a
local or systemic disease or disorder. Environmental and pharmacological stimuli have
been shown to change cellular and molecular reactions in tissues and body fluids (Seigel,
51993; Mednieks et aI, 1993). Therefore, secretory protein levels in saliva may be used as
an index of metabolic responses of salivary exocrine cells to systemic stimuli (Mednieks
and Hand, 1982). This is achieved by studying events mediated by cyclic AMP (cAMP),
through cellular events associated with changes in the cAMP receptor proteins.
This study was carried out to measure levels of secretory proteins in saliva and
gingival crevicular fluid of children, the presence of the cAMP receptor proteins (cARP)
in oral fluid, the ratio of total protein to cARP, and to determine if developmental stages
influence their expression.
Techniques for collection of saliva
Many of the advantages of analyzing saliva relate to the non-invasive nature of
the collection procedure. For the collection of samples from children, mixed whole saliva
is the only practical alternative. Several methods have been described for the collection of
mixed saliva.
In healthy subjects, gingival crevicular fluid (from the tooth/gum margin) may
constitute up to 0.5% of the volume of mixed saliva. This proportion may markedly
increase in patients with gingivitis (Cimasoni, 1974). Plasma exuding from minor
abrasions in the mouth may also contribute to saliva. The protein content of gingival fluid
is similar to that of plasma. Therefore, it is usually recommended that subjects should
not brush their teeth or practice any other methods of oral hygiene for several hours
before collecting a saliva sample.
Although most patients prefer donating saliva rather than blood, a substantial
social barrier exists to "spitting". For this and other reasons, subjects often experience
6decreased salivary secretion (dry mouth) if asked to provide a sample. Many researchers
have found it advantageous to further stimulate salivation and a number of stimuli have
been used.
Chewing paraffin wax, Parafilm (American National Can., Chicago, IL), rubber
bands, pieces of Teflon or chewing gum (Dawes and Macpherson, 1992) will usually
elicit a flow of 1 to 3 ml/min. Mucklow (1982) recommends that, when these types of
stimuli are used, the subject should allow saliva to accumulate in the mouth until the
desire to swallow occurs, at which time the fluid can be expelled smoothly into a vessel.
Expectorations should be avoided since this introduces bubbles, which may result in
changes in pH and contaminate saliva with secretions of respiratory epithelium leading to
errors in interpretation of the saliva/plasma concentration ratio (SIP ratio). The use of
acid lemon drops or a few drops of 0.5 molll citric acid are among the most potent of
taste stimuli and will generally induce a maximal secretion of 5 to 10 mllmin (Vining and
McGinley, 1985). In general, the secretion rate increases with the size of the bolus and
the pressure required to chew it. If chewing is unilateral, then the glands on the active
side may secrete copiously while those on the inactive side secrete very little. For studies
reqlliring high saliva flow rates for extended periods of time, secretion-stimulating drugs,
such as the parasympathomimetic drug pilocarpine, have sometimes been used orally,
subcutaneously, or intravenously. Administration of2.0 mg/kg pilocarpine resulted in
sufficient flow to collect (by capillary tube) 5 ml of saliva per rat.
7Special devices
Within the last few years, much research has been done to develop a method that
solves many of the existing problems in using saliva for the quantitative determination of
the "free" (= non-protein bound) component of drugs. Cooper et al (1981) and May et al
(1978) were the first to use a dental cotton roll to collect saliva in order to monitor
desipramine. Over the years their method has undergone some improvements, and the
dental cotton roll is currently available as the Salivette®. The advantage of the Salivette®
over many other sampling devices is that it reliably absorbs a relatively large volume of
saliva (1.5 mt) in a short time (Hold et aI, 1995). The OraSure®, another collection
device, absorbs only 1.0 ml and, moreover, collects a mixture of gingival crevicular fluid
and saliva rather than saliva alone, since the pad is placed between cheek and gums. The
term "oral sample" is used rather than saliva when the OraSure® device is used (Thieme
et ai, 1992).
An Oral-Diffusion-Sink (ODS) device is used for the in situ collection of an
ultrafiltrate of saliva (Wade, 1992; Wade and Haegele, 1991). The ODS device, a
variation on an earlier design developed for time-integrated measurement of
corticosteroids in interstitial fluid (Wade, 1984), is worn in the mouth and continuously
accumulates the compounds of interest as they diffuse into the device along a
concentration gradient.
Schramm and coworkers (1990) developed a device for the in situ collection of
an ultrafiltrate of saliva. The collecting device is based on the principle of an osmotic
pump. A semi-permeable membrane encloses an osmotically active substance (sucrose),
8that within a few minutes of being put into a patient's mouth, draws an ultrafiltrate of
saliva into the device (1 ml of ultrafiltrate after 5 min). The drawback to all these devices
is that they all adsorb proteins from a solution to a greater or lesser extent and are
therefore unsuitable for studying protein expression.
Gingival crevicular fluid
Gingival crevicular fluid (GCF) is found within the gingival crevices that encircle
the teeth and has components that point to serum as its origin. In healthy individuals, the
GCF is separated from the whole saliva by the free marginal gingiva. The composition of
GCF, therefore, is considerably different from that of the other oral fluids. The proteins
present in GCF have been studied by a variety of techniques. Sueda et al (1966)
demonstrated histochemically that crevicular fluid contains proteins similar to those
fOllnd in serum. However, the concentration of proteins in GCF is significantly lower
than that of serum (Marcus et aI, 1985).
Since the flow rate of GCF has been shown to increase with inflammation, it has
been suggested that GCF may be useful in the diagnosis of inflammatory diseases within
the oral cavity. Its measurement makes it possible to treat periodontitis in its earliest
stages, before irreversible changes occur in the supporting periodontal tissues.
Additionally, GCF may be useful in the diagnosis of systemic diseases. For example, it
has been demonstrated that both GCF and blood glucose levels are elevated in diabetic
patients (Kleinberg and Golub, 1985).
9Current techniques in GCF collection and quantification
Since the amount of GCF obtainable from clinically healthy gingival sulci is
extremely small, the collection of sufficient GCF for analysis poses particular problems.
Most investigative procedures require that samples from different sites be combined in
order to provide sufficient GCF for analysis. Currently, there are only a few widely
accepted techniques for the collection ofGCF. The most common method ofGCF
collection is described by Offenbacher et al (1986). In this technique, paper strips (Perio
Paper, Harco~ Tustin, CA) are inserted about Imm into the gingival crevice. An
alternative method is to use glass capillary tubes. In this technique, a thin glass capillary
tube is inserted under the free gingival margin and the GCF is allowed to enter the tube
for a period of time (Marcus et aI, 1985). In each technique, there is considerable
variability in the suggested amount of time needed for collection. Some investigators
suggest collecting for a little as 20 seconds, while others suggest as much as 90 minutes
(Cimasoni, 1974, 1983). Egelberg (1966) noted, however, that during the lengthier
collection periods, the filter paper or capillary tubes might cause local irritation, resulting
in an inflammatory response, which interferes with the normal tissue fluid dynamics in
that area.
The analysis of individual proteins in GCF can be accomplished with many
different techniques. In immunoelectroplloresis, the sample is placed in a gel containing
antibodies to the particular protein being quantified, and an electric field is applied to the
gel. The protein of interest would be identified using a dye that would stain the antibody-
antigen complexes (Marcus et aI, 1985). Radioimmunoassays are also employed in the
quantification of individual proteins. The principle of radioimmunoassay is that proteins
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in the GCF sample compete with radioactively labeled proteins for a limited number of
sites on antibodies to the protein (Grieve et ai, 1994). Enzyme linked immunosorbent
assay (ELISA) kits are also popular in the quantification of proteins in GCF, but the
experiments are complex and time consuming.
Cyclic AMP- dependent Protein Kinase (PKA)
Cyclic AMP dependent protein kinase is also known as protein kinase A (PKA).
PKA participates in the regulation ofvarious cellular activities (Flockhart and Corbin,
1982), and is able to catalyze phosphorylation of a number of cellular proteins. PKA is
influenced in response to either hormonal or ~-adrenergic stimulation. Cyclic 3', 5'-
adenosine monophosphate (cAMP) is responsible for the activation ofPKA in a series of
steps. First, a neurotransmitter arrives at a cell membrane and binds to a transmembrane
receptor. This bound transmembrane receptor causes conformational changes in G-
proteins on the inner cell membrane, activating adenylate cyclase. Adenylate cyclase
catalyzes the formation of cyclic AMP from adenosine triphosphate (ATP), and finally,
PKA is activated by cyclic AMP (Lehninger et aI, 1993).
The metabolic effect of elevated intracellular cAMP, therefore, is the
phosphorylation of serine or threonine residues of specific proteins by PKA. However,
changes in the levels of cAMP due to hormonal or pharmacological stimulation are only
transient. The binding of cAMP to regulatory (R) subunits ofPKA can be measured
reliably and is a useful index of the stimulatory effects ofPKA (Hoyers et aI, 1980;
DeCamilli et aI, 1986). Two isozymic forms of PKA were identified by their differing R
subunits, type I, termed RI and type II, termed RII (Scott et aI, 1987; Taylor et aI, 1990).
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The activity of PKA is dependent on the dissociation ofan inactive holoenzyme tetramer
in the presence ofcAMP. This dissociation can be represented in the following equation,
R2C2 + 4 cAMP ~ 2R-cAMP2 + 2C
where, R2C2 is the inactive holoenzyme with two regulatory (R), and two catalytic (C)
subunits. In the presence of cAMP, the regulatory subunits are occupied ( R-cAMP2) and
are referred to as cARP; and the catalytic subunits are free to catalyze phosphorylation
(Flockhart and Corbin, 1982; Mednieks et aI, 1997).
Distribution of Cyclic AMP-dependent Protein kinase
Within cells, PKA is present in both the nucleus and the cytoplasm (Steiner et aI,
1978). It was documented by DeCamilli et al (1986) that after appropriate stimulation,
both Rand C subunits might translocate from one cellular compartment to another. The
regulatory subunit of type II PKA (RII) is known to be present in both human and animal
saliva in relatively large quantities (Mednieks and Hand, 1984; Mednieks et aI, 1994).
Mednieks et al (1987) used immunocytochemical labeling to show the distribution ofRII
in rat parotid acinar cells. In this study, a polyclonal antibody to RII was utilized to
determine the distribution ofRII, which was shown to be present in the nuclei,
cytoplasm, rough endoplasmic reticulum, Golgi apparatus and secretory granules, but
generally not in mitochondria. This study confirmed the localization ofPKA within
parotid cell nuclei and established the secretory granules as the source of the PKA
regulatory subunits in saliva.
Further work has shown RII to be present in several other types of exocrine and
endocrine cells of the rat such as the pancreas, seminal vesicles, pituitary gland cells and
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intestinal cells. This widespread occurrence of the PKA regulatory subunits in secretory
granules suggests, that in addition to its role in intracellular regulatory functions such as
secretory events, RII may also function extracellularly (Mednieks et aI, 1989).
Changes in PKA levels in response to environmental stimuli
Previous studies indicate that environmental and pharmacological stimuli may
lead to changes in the amount and distribution of PKA in secretory cells. An in vitro
study showed that rat parotid acinar cells were responsive to isoproterenol, an analog of
norepinephrine, and a strong f)-adrenergic agonist. Incubation of rat parotid gland pieces
-6
with 10 M isoproterenol resulted in significant changes in the localization ofPKA
proteins within the parotid acinar cells (Mednieks et aI, 1982).
It was shown that RII levels in rat saliva were sensitive to pharmacologic
stimulation in vivo. Saliva was collected from a group of rats injected with 30mg/kg
isoproterenol. Each sample was labeled for identification ofR proteins and the proteins
were separated and quantified by polyacrylamide gel electrophoresis. This study showed
that the saliva of rats injected with isoproterenol contained high levels ofRII, indicating
that R proteins are released during exocytosis (Mednieks and Hand, 1984).
Environmental stimuli also have been shown to correspond with changes in PKA
levels. Experimental animals subjected to periods of microgravity had significant
changes in R subunit levels within heart muscle cells (Mednieks et aI, 1991).
It has also been demonstrated, that levels ofR subunits in human saliva are
affected by auditory stimulation. Volunteers were subjected to high-decibel sound for a
brief period of time. Salivary levels rose sharply immediately after the auditory stress was
13
initiated. Forty-eight hours after the cessation of the high-decibel sound, the R levels
returned to original baseline levels (Mednieks et ai, 1994).
Most recently, work from our laboratory indicates that the levels of salivary R
subunits can be easily and reproducibly determined using samples from a variety of
human subjects (Sivakumar et aI, 1999; Burke et aI, 2000).
Saliva as a diagnostic fluid
Saliva is increasingly used for a variety ofdiagnostic purposes. Michaels (1901)
and Kirk, (1903) were perhaps the first to examine the usefulness of saliva in diagnosis
by attempting to use saliva in the recognition of certain abnormal states and as an index
of faulty metabolism. Since drugs and their metabolites appear in saliva, the fluid is
useful in monitoring of drugs. Pharmacologically active drugs are usually unbound.
Saliva differs from plasma in that it contains only unbound drug. Therefore, saliva may in
some instances, reflect therapeutically active drug concentration more closely than
plasma (Siegel, 1993). Cone (1993) showed that many drugs of abuse, including alcohol,
are easily demonstrated in saliva.
Katz and Shannon (1969) demonstrated the feasibility of assaying steroids in
saliva. They showed that steroids in saliva could be measured with adequate precision.
The lipid-soluble unconjugated steroids pass readily into saliva and their concentrations
are proportional to plasma concentrations. Since this discovery, collection of saliva for
estimation of steroid concentrations has been part of routine monitoring of persons for
such conditions as delayed puberty, adrenal hyperplasia and Addison's disease
(Malamud, 1992).
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Mandel, in a review (1993), described the changes in salivary composition that
are closely associated with cystic fibrosis. These patients have markedly increased levels
of calcium, phosphate and proteins in their submandibular saliva. Doering et al (1977)
also found that children with cystic fibrosis exhibited unique electrophoretic salivary
banding patterns, indicating that this disease appears to permanently alter the expression
of secretory proteins.
OBJECTIVES
Working Hypothesis
Since secretory proteins in saliva show heterogeneity, varying from person to
person, their expression is apparently individually regulated.
Null Hypothesis
There is no difference in the expression of secretory protein present in whole
saliva and gingival crevicular fluid of children and adults
Experimental Design
In order to carry out the stated objectives, it was necessary to devise reliable
procedures for the collection and analysis of secretory proteins in saliva and gingival
crevicular fluid. The experimental design entailed developing collection methods of oral
fluids (whole saliva and GCF) that were feasible for clinic use. The first criterion was that
the method should be rapid and reproducible since it involves children. The next major
consideration was that it should be harmless, non-invasive.
The analytical phase required refinement of existing techniques ofelectrophoresis
and immunoblotting. The design involved miniaturization of the electrophoretic
separation methods to successfully run gels with small amounts of samples.
15
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Specific Objectives
1. To examine the expression of salivary protein and measure the level of cARP in
children's saliva.
2. To provide information about similarities or differences in specific salivary
proteins between children and adults.
~IATERIALS AND METHODS
Patient Selection Criteria
Adult and children volunteer patients between the ages of six and fifteeen at the
pediatric dental clinics in the Connecticllt Children's Medical Center, Burgdorf dental
clinic and a private dental office (Children's Dental Associates), who were healthy and
not taking any medications, were eligible for inclusion in this study. Individuals
volunteered to participate in the study and were not compensated in any manner. All
samples were collected from cooperative patients, who were able to follow instructions.
In addition, all participants in the study were required to have a healthy periodontium as
indicated by a lack of plaque and bleeding on probing with either a periodontal probe (in
adults) or Perio Paper®. Whole saliva and GCF were collected from patients before recall
procedures to avoid any contamination from topical fluoride application. Samples from
patients found to have new carious lesions or gingivitis were not used. All patients
meeting the above criteria were used regardless of race or gender.
A total of 49 samples were included in the study. GCF and whole saliva were
collected after obtaining informed consent prepared in accordance with NIH and the
University of Connecticut guidelines (IRB reference # 98-177) involving human subjects.
Signatures were obtained from both the parent and the patient in accordance with the
protocol. The samples were coded, to protect the privacy of the donors. The IRB
protocol, a sample Informed Consent form and the IRB approval letter are included in
Appendix 1.
17
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Sample collection
Subjects with clinically normal gingiva were used in the study. The examination
and sample collection were perfonned in a dental chair with good lighting. Sample
collection always preceded clinical evaluation and probing which prevented any
contamination with blood. Samples of GCF were collected from the gingival crevices
around four teeth using medium paper points (Mynol®). The collection sites were
isolated with cotton rolls and gently dried with an air syringe to minimize the
contamination of saliva. The mesial and distal surfaces of either upper or lower incisors
and canines were used. Canines were the preferred teeth, but if not present, incisors were
used. A total ofeight paper points were inserted in these sulci for approximately 5-10
seconds or until the paper points were wetted. Care was taken to avoid any mechanical
irritation of the gingival crevice. The paper points were then removed and inspected
visually to make sure that they were 'wetted' sufficiently and that they had no blood on
them (evidence of mechanical injury). Only the very tip (2-3 mm) of the points were
expected to be wetted by the GCF.
A portion of each paper point containing GCF was then clipped with a sharp
sterile scissors approximately 1 mm above the point of 'wetting' and immediately
inserted into a vial containing 25 JlI of sample buffer (200/0 glycerol, 1% SDS, 0.2% B
mercaptoethanol and 0.1% bromophenolblue) and protease inhibitors (5 J..ll phenylmethyl
sulfonyl fluoride).
An illustration of the GCF collection method is shown in Figure 1. In our pilot
studies we used Peno Paper® to collect GCF, but discovered that it was very
difficult to recover the sample from the paper. We then tried paper points, and this
19
approach improved collection and recovery, but was not sufficient to load the gel with
confidence. Finally, we cut the paper point to 1 mm above the wetted area. This avoided
absorption of most of the sample buffer by the dry end of the paper point allowing more
proteins to be eluted into the buffer and a more concentrated sample for analysis. The
other advantages of collection of GCF with paper points are that the wetted area can
clearly be visualized and once it is cut, the loss of sample in the paPer point is minimal.
Our experience shows that as much as 20-22 J.!l (out ofa total of25 J.ll) of the sample
can be recovered using this method. The sample buffer and the protease inhibitor
prevented the breakdown of the proteins.
The vial containing the sample buffer and the eight paper points was boiled in the
clinic for five minutes and stored in ice until the end of the day. The samples were later
transported to the lab and stored at -20oe.
Whole saliva was collected in a sterile cup. The subject was advised to
swallow, take a drink of water (2-3 ounces), and then thoroughly rinse the mouth with
cool water. After rinsing, the subject was given a collecting container and saliva was
allowed to accumulate by bending the head forward and allowing it to drain into the cup.
The saliva was collected passively with no active expectoration. The purpose of the
above procedure was to avoid any upper respiratory contamination of the sample. Using a
mechanical pippete, 25 J.ll of the sample was immediately transferred to a vial containing
an equal amount of sample buffer and a protease inhibitor (5 J.!l ofPMSF). The sample
was then boiled in the clinic and stored in ice, while the renlaining salivary sample was
transferred to another vial and stored similarly.
Each sample was then transported to the laboratory and given a numerical code
without using identifiers linked to the subject. The samples were then stored at -20°C
20
until the time of laboratory analysis. Laboratory analysis of the sample was generally
performed within 72 hours.
Sample preparation
The samples were removed from -20°C, thawed at 4°C, and boiled for
approximately 2-3 minutes. During the subsequent preparative steps, the samples were
maintained in ice. After centrifugation of both the saliva and GCF samples for
15 minutes, 3 JlI of EDTA was added to the saliva sample to chelate calcium ions (this
reduced the viscosity and allowed for easier and more consistent loading of the sample in
the gel). The samples were then vortexed for approximately 15 seconds to achieve a
consistent mixture and then placed on ice.
Determination of protein concentration
The protein concentration of each sample collected was determined to compare
samples reliably. The samples were removed from ice, and 1.5 Jll of each salivary and
GCF sample was "dot blotted" onto a nitrocellulose membrane. Proteins and complexes
containing proteins readily and reversibly bind to nitrocellulose membranes.
Additionally, 1.5 Jll each of various concentrations bovine serum albumin (BSA) were
"dot blotted" on the nitrocellulose membrane as controls (0.1, 0.25, 0.50, 1.0, 2.5, 5.0 and
10 mg/ml). This nitrocellulose membrane was allowed to dry and then immersed in 2%
Ponceau S (Ponceau solution: Ponceau-S 2 g ( 2%), Trichloroacetic acid 30 g (30%)
Sulfosalicylic acid 30 g (30%), deionized water to ]00 ml) red dye for five minutes.
The Ponceau S red dye was selected for use to stain proteins instead of the
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traditional Coonlassie stain because it can be removed by washing and the same
membrane later used for Western blotting. This avoids the neccessity to create a sister gel
which would require dividing the small GCF sample between two gels. Also, Ponceau
S stains certain salivary proteins, ie, the proline-rich proteins, that fail to adequately
stain with Coomassie blue. Each of the samples stained red with different intensities.
The density was directly correlated to the total amount of protein in the sample.
Separation of proteins by SDS-PAGE
Sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) is widely
employed in the analysis of proteins. Traditional SDS-PAGE methods were adapted to
study human salivary secretions. We used denaturing SDS-PAGE gels under reducing
conditions by a modification of a previously reported method (Mednieks et aI, 1994).
SDS-PAGE can resolve complex mixtures into distinct bands on a gel. The position of
the protein band along the lane gives a good approximation of its size, and after staining
the band density is a rough indicator of the amount present in the sample. The standards
and reagents used in this and the subsequent analysis were purchased from Sigma
Chemical Company.
Mini gels were prepared according to the vendor's specifications (BioRad Corp).
The dimensions of the gels were approximately lOcm x7cm x1.5mm. A glass plate
sandwich, assembled using two clean plates and two 0.75 mm thick spacers on each side,
placed one on top of the other, was locked to a casting stand. This allowed for the
creation of a 1.5 mm spacer and a 1.5 mm gel. A 10% running gel solution was prepared
and pipetted into the glass plate sandwich to a height of approximately 10 mm. This
acted as a stop or a plug, over which the running gel was poured.The 10% running gel
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(prepared with the following mixture 40% acryl/Bis 2.5ml, 1.5M Tris-Hel, pH 8.8 2.5ml,
10% SDS 100JlI, deionized water 4.83 ml, tetramethylethylenediamine (TEMED) lOJ.!l,
ammonium persulphate (APS) 83J.lI) was pipetted between the glass plate another 7cm.
This was over-Iayed with water to create a sharp interface.
The gel takes approximately15-20 minutes to fully polymerize and once it has
polymerized, the overlay of water is removed and a stacking gel (40% acryl/Bis 125 JlI
0.5 M Tris-Hel, pH 6.8315 J.!l, 10% SDS 13JlI, deionized water 795 J.!l, TEMEDI J.lI,
APS 8J.11) is prepared and loaded another 1em. A 1.5 mm comb with 12 teeth was then in
serted in between the glass plates,taking care not to trap any bubbles below the teeth of
the comb. The gel was allowed to sit for at least an hour before it was wrapped in a
cellophane sheet and stored in the refrigerator overnight at 4°C.
The whole saliva and GCF samples were briefly vortexed and loaded'in the wells
with a micro-pipette. Additionally, 3.0 J..ll of a protein standard marker (Rainbow
Standard®, Amersham, Glenview, IL) was added to the first well for the estimation of
protein sizes within a set of samples.The combs were removed after 24 hours and the
wells were rinsed with de-ionized water. The sample containing equal amounts of
sample buffer was then loaded depending on the density of the dot blotting (see below).
On average, 20 J..lI of GCF and 25 fJ.I of salivary sample were loaded in each well. The
salivary and GCF samples of the same patient were loaded side by side to have a visual
comparison of the banding patterns of the two fluids. The polymerized gel sandwich was
then attached to an upper buffer chamber using the manufacturer's instructions. The
upper buffer chamber was filled with Ix SDS electrophoresis buffer, and the attached gel
sandwich was placed in a lower buffer chamber also filled with the same buffer. After
the samples were loaded, electrophoresis was carried out at 30 rnA for 3 hours.
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The SDS PAGE gel was then prepared for transblotting in order to transfer the
electrophoretically separated proteins from the polyacrylamide gel to a nitrocellulose
membrane. An electric current was applied perpendicular to the gel causing the proteins
in the gel to migrate horizontally onto the nitrocellulose membrane (Towbin et aI, 1979;
Mogi et aI, 1986). Care was taken to avoid trapping of air bubbles between the gel and
the nitrocellulose by rolling a clean test tube over the membrane. The assembled
transblotting cartridge was submerged in transblotting buffer (10% 1M Tris without SDS,
pH 7.6,20% ethanol, 70% water), connected to power supply and run at 100 rnA for
2 hours. Generally the proteins are negatively charged and will transfer from the
cathode to the anode.
At the completion of transblotting, the nitrocellulose membrane was removed
from the cartridge and gently rinsed in distilled water. The membrane was then placed in
a 2% Ponceau S red dye for 5 minutes. The excess dye was rinsed away and the protein-
banding pattern could be visualized. The presence ofvisible Rainbow standard remaining
on the gel indicates that a small amount of protein may not have been transferred. These
gels were stored in a box containing Coomassie blue solution (0.025% Coomassie
brilliant blue R 250, 400/0 methanol, 7% acetic acid) as a reference for identification of
the original banding patterns.
Densitometry
Densitometric analysis of the dot blots was accomplished by using a flat bed
color scanner and NIH Image software (developed at the u.s. National Institutes of
Health and available on the internet at http://rsb.info.nch.sw/nih-image/).This allowed us
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to estimate the amount of protein in the sample by creating a standard curve of known
BSA concentrations.
Sample concentrations can be determined using optical, electronic, and for our
purposes, a computer based imaging technique. Densitometry science was described
originally by Bouguer and Lambert who noted loss of radiation (or incident
light/transmitted light) in passing through a medium. Later, Beer found the radiation loss
in a medium was a function of the substance's molarity or concentration. According to
Beer's law, concentration is proportional to optical density (aD). According to Beer's
law, the density of a point is the log ratio of incident light upon and transmitted light
through, represented by the formula
aD == Loglo (10/ II)
The NIH Image densitometric software conforms to Beer's law and estimates the
total protein content of "dot blots". The salivary and GCF lanes on the nitrocellulose
membranes were analyzed and plot profiles of every band in the lane were produced in
the form of a graph. Densitometric values for a particular band or a lane were obtained
using the formula
(A x BKG) +ID ==Av. Dens
where, A ==Area, BKG == Background, ID == Integrated density and AV. Dens == Average
density. Since the value of total protein is known, the ratio of cARP/total protein can be
obtained using the same methods.
The nitrocellulose membranes containing the dot blots of both the samples and
the known BSA standards were scanned and the image was saved on the computer hard
drive. Next, a density profile of the BSA dot blot was produced. This was repeated for
each different concentration of the BSA dot blots. The computer-generated density
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profile produced a graphic representation as well as a numeric value for the average
density of the BSA. Next, the average density values ofeach different concentration of
BSA were graphed to produce a standard curve. This standard curve was then used to
estimate the protein concentration of each individual sample by visually comparing the
intensity of each sample stained. The total proteins of the salivary and GCF samples
were then loaded for electrophoresis based on the calculations using the value in the
linear portion of the standard curve.
Western blotting
The nitrocellulose membranes containing the total protein dot blots as well as the
proteins separated PAGE were Western blotted for identification of the R subunit of
PKA. The nitrocellulose membranes were washed with 0.015 M phosphate buffer
solution and distilled water for about 5 minutes to remove the Ponceau S red dye. The
membranes were incubated in 5X TeloBlot (non-mammalian proteins 4% w/v, sodium
azide 10-6M, 0.5% Tween 20 detergent) for 1 hour to block the non-specific binding sites.
The secretory proteins on the membrane were identified with Western blotting by a
modified method of Szczepanski et al (1998). Briefly, the membranes were incubated in
a solution of rabbit anti-rat RII (1 :500 dilution) in phosphate buffered saline solution
(PBS) and 0.5X TeloBlot at room temperature for 1 hour and then at 4°C overnight. The
membranes were washed with 3 changes ofPBS to remove non-binding primary
antibody. A secondary antibody (goat-anti rabbit IgG) conjugated with horseradish
peroxidase (J-IRP) diluted in PBS-O.5X TeloBlot was added and the membrane incubated
for 1 hour at room temperature. The membrane was washed with 3 changes of PBS.
Diaminobenzidine-H20 2 (6mg DAB, 10ml 50mM Tris [pH 7.6], 15 J-ll 30% hydrogen
peroxide) was added to the membrane and incubated at room temperature for 1-5
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minutes. A bro\\lJ1 reaction product identified the specific protein on the membrane. The
membrane was then removed from the solution and rinsed with distilled water and dried.
The Western blots vvere scanned into a computer file and densitometric analyses were
performed as described previously.
RESULTS
The results of this study are in two main categories. The first part reflects the ratio
determination of total proteins to that of cARP as measured by "dot blotting". Next, the
relationship of total protein banding patterns and cARP was determined by
electrophoresis and Western blotting.
Protein concentration of whole saliva and GCF
A standard curve of protein concentration was developed using measured amounts
of bovine serum albumin and their numerical values were plotted as shown in Fig 2.
These results indicate that the obtained values were in the linear range and can be used to
calculate protein concentrations of the samples. Fig 3 shows dot blotting ofwhole saliva
samples (panel A) and immunoblotting with anti RII antibody (panel B). Note that
samples 14 and 15 are BSA and (l- amylase, respectively, and do not show in panel B.
The comparison of traditional Coomassie blue dye staining method with that of
Ponceau S used in the study is presented in Fig 4. Although the signal in the membrane
using Ponceau S is apparently weaker, the banding pattern analysis (panel C) shows that
the majority of the peaks are present, indicating that this method can be used without loss
of information.
The procedures shown in Figs 3 and 4 were applied and digital files of the dot
blots of whole saliva and GCF samples were subjected to densitometric analysis using
OFOTO and NIH Image software. The average density of each sample was calculated.
Since the average density of each dot blot was directly correlated with the protein
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concentration of the sample, calculations of the protein concentrations were made from
these average density values. The total concentration of protein in 49 whole saliva
samples is shown in Figs 5 and 6. The average density was in the range of 0.14-2.81, in
arbitrary units. This corresponded to actual salivary protein concentrations of2.5-5.0
fill/mg.
Twenty-five samples ofGCF were analyzed for total protein content (Fig 7). The
protein concentration ranged from 0.24-1.82 in arbitrary units. The range was
comparable to that of saliva. The dilution factor, however, is 10 fold for GCF, therefore
the protein content ofGCF is 10 times greater than that of saliva (unpublished
observation, M Mednieks and J Burke, Chicago, IL).
The mean values of proteins in saliva (n==49) and in GCF (n==25) were obtained
and the standard deviations were calculated. Table 1 shows the mean value of total
proteins in saliva (0.885) and that ofGCF (0.636) in arbitrary units. Their standard
deviations were calculated to be 0.61 and 0.37 (Fig 8), respectively.
Immunoblotting was carried out using the dot blots to identify total proteins and
quantify cARP (Figs 9,10). The values are compared in Figure 11. In all the samples
tested, cARP was consistently present. The percentage of cARP to total protein was
reasonably consistent with a mean percentage of2.69 (Fig 12). The range of cARP in
samples varied from 0.010-0.48 in arbitrary units, whereas the values for total protein in
the same samples of saliva ranged from 0.46-2.62 (arbitrary units). The amount of cARP
in total protein varies from 0.5-3.0% of total protein.
The total protein concentration of whole saliva of male and female subjects was
compared. The range for male children was 0.24-2.62 (Fig 13) and that for females was
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0.19-2.69 (Fig 14) in arbitrary units. The mean value for males (n==22) was 1.017 and for
females (n==27), 0.792 (Table 2). The standard deviations were 0.662 and 0.574 (Fig 15),
respectively. A two-tailed t-test was done and the difference in values for males and
females was not statistically significant (p > 0.05).
The difference in concentration of proteins between the three ethnic groups in the
study is shown in Figs 16-18. Protein concentrations of Caucasian children with
European background (EC) were in a range of 0.2-2.69. Protein concentrations of
Hispanic/Latino (H/L) background children were in the range of 0.14-1.11, and those of
African American (AA) background children, 0.19-1.11 in arbitrary units. The mean
values for each of these ethnic groups were EC (n=23) 1.13, H/L (n==15) 0.681 and AA
(n==11) 0.559 (Table 3). The standard deviations for these groups were 0.755,0.330 and
0.302, respectively (Fig 19). Analysis ofvariance was perfonned and there was a
statistically significant difference in the concentration of proteins between the Caucasian
group and the other two groups (p < 0.05).
Samples were divided into two age groups (6-9 and 10-15) based on their stage
of mixed dentition. The values for the 6-9 age group ranged from 0.16-2.69 (Fig 20). The
10-15 age group had a range of 0.2-2.62 (Fig 21). The mean values for the 6-9 age group
(n==29) was 0.762 and for the 10-15 age group (n==20) was 0.995 (Table 4); their standard
deviations were 0.537 and 0.698, respectively (Fig 22). A two-tailed t-test revealed that
the difference between the two groups was not statistically significant (p> 0.05).
General Protein Banding Patterns
Saliva and GCF samples from each individual were collected and
electrophoretically separated. A densitometry profile for each lane of the SDS gels was
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produced with NIH Image software. Protein banding patterns of children's saliva samples
were analyzed using densitometry and a PAGE pattern is shown in Fig 23. Protein
banding patterns and Western blots of different adult human saliva have shown that the
banding pattern is varied for each individual donor. Thus, the expression of salivary
secretory salivary proteins appears to be unique in each individual.
Panel B shows the same membrane after immunoblotting for cARP. RI is more
consistently seen in all samples of children's saliva. This differs from adult samples,
which show predominantly RII (Sivakumar et ai, 2000).
Densitometric analysis of the Ponceau S stained PAGE samples (Fig 24) shows
the consistent presence of a peak at 90 kD, which was not seen in adult samples. Also in
these graphs is a peak in the 45-50 kD region, which is the relative mobility ofR!. Some
adult samples did not have a peak in the 55 kD areas (Sivakumar et ai, 2000) which
represents the relative mobility of a-amylase, whereas virtually all children's samples
had a-amylase.
Except for the differences noted above, banding patterns in children presented a
similar pattern to that of adults. There were no consistent, qualitative differences seen
among different age, sex or ethnic groups.
In panel A ofFig 25 the PAGE patterns for 5 children's whole saliva and GCF
samples are seen. The first and the last lane are Rainbow standards. Lanes 1-10 represent
alternating banding patterns of children's whole saliva and GCF. The whole saliva lanes
consistently showed a band with the relative mobility of a-amylase. This band was
consistently absent in GCF. A slower moving band similar to serum albunlin was
consistently present in GCF, but absent in whole saliva. These results demonstrate the
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integrity of the loading technique. More importantly, these results show the segregation
of children's oral fluid (saliva and GCF) in fully separate compartments. Densitometric
analysis of five whole saliva and five GCF samples is shown in Fig 26. The presence of a
peak at the relative mobility of a-amylase is seen in all saliva samples but not in GCF.
Panel B, Fig 25, shows the Western blot for cARP ofaltemate samples of whole
saliva and GCF. A consistent pattern ofRI was seen in whole saliva whereas various
combinations ofRI and RII were seen in GCF, as would be expected in serum.
Densitometric analysis done on the Western blot of these samples (Fig 27) clearly
demonstrates the presence of only RI in whole saliva of children.
Summary
Secretory protein expression in children's saliva showed notable differences to
that of adults.
1. Qualitatively, a low mobility (---90 kD) band was seen in the majority of saliva
samples from children and only in fewer than 20% of the adults. This difference
may be due either to a larger proportion of submandibular/sublingual saliva
(which contains more high molecular weight glycoproteins than parotid saliva) or
to less proteolytic degradation in children's saliva than in that of adults.
2. Adult samples had variability in the presence of a-amylase whereas all children's
saliva had a band consistent with the mobility of a-amylase.
3. Most notably, children's saliva contained predominantly RI which is different
from adult saliva which contained predominantly RII.
DISCUSSION
The majority of early studies on salivary glands and saliva has been carried out
using tissues from laboratory animals or pooled human saliva. The resulting protein
profiles in humans appear to be similar to those found in other species (Beely, 1991;
Bennick, 1982). This study shows that protein expression in humans may be quite
complex, regulated by catecholamine hormones via the cyclic AMP pathway with
developmentally distinguishing features significantly different from those of rodents.
In recent studies it has been demonstrated that developing salivary glands undergo
extensive morphological and functional differentiation (Sivakumar et aI, 1998; reviewed
in Denny et aI, 1997). The secretion of proteins, regulated by beta adrenergic responses
via cyclic AMP, can serve as an index to differentiate acute from chronic stress
responses: namely, the expression of cAMP receptor proteins reflect the responses in an
apparent proportional manner (Mednieks et ai, 1982, 1991). Moreover, immediate
responses such as mechanical stress are also mediated via the cAMP pathway (Uematsu
et aI, 1997; Burke at ai, 2000). It remains to be determined in future studies if secretory
responses to pharmacological or environmental stress in children are comparable to those
of adults.
As little data are available regarding the protein profiles of GCF in general and
the expression of secretory proteins in children, the basic aims of the study were to
investigate these parameters. The findings were unexpected in that adult and children's
saliva exhibited unique individual protein profiles. Moreover, a major salivary protein,
alpha amylase, varies extensively, being entirely absent in some adults. In children, the
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protein appears more stable as indicated by the consistent finding of a protein with the
relative mobility of alpha amylase. The prevalence of large molecular weight proteins in
the saliva of children may indicate that there are differences in either the expression or
activation of proteases. This is supported by apparent stability of amylase in saliva of
children compared to that of adults.
Notable differences in the expression of another secretory protein in children
were observed, a large (r-v90 kD) band in the majority of saliva samples from children and
only in fewer than 20% of adults. This may be due to developmental differences in
expression of protein, a larger proportion of submandibular/sublingual gland secretion
(which contains more large kD glycoproteins than parotid saliva) in children's saliva, or
there is less proteolytic degradation in children's saliva than that of adults.
By performing densitometry and analyzing the total protein content of saliva and
GCF, it was found that there was no difference between males and females and the
different age groups (divided based on stage of mixed dentition). However, there was a
small, but statistically significant difference in the concentration of protein between
Caucasians and the other two groups (Hispanics and African Americans). This, however,
has to be substantiated by testing larger sample populations.
Interestingly, and very significantly, children's saliva expressed predominantly
RI, whicll is different from adult saliva, which expressed RII predominantly. These
developmental changes may reflect that whole saliva of children has a different
composition (more submandibular/sublingual) than adults. It may also indicate that
children's salivary glands may be undergoing developmental changes even between 6-15
years of age.
34
Effectiveness of paper point collection method
In pilot studies Perio Paper (Harco,Tustin CA) was used to collect GCF. It was,
however, very difficult to recover the sample from the Perio Paper. Paper points were
then tried and this approach improved collection and recovery, but the recovered protein
was not sufficient to load the gel with confidence. Finally, we cut the paper point to Imm
above the wetted area (Fig 1) limiting diffusion ofGCF to a small paper area which
could be extracted with 25 JJ,1 of buffer. The use of sterile paper points for the collection
of GCF has many advantages over the traditional collection methods. The paper points
are narrow, cylindrical and flexible. They are also available in many different sizes.
Typically, the tip of the paper point will have a diameter of 1 mm, which is much smaller
than the Perio Paper strip. The small tip of the paper point allows it to be easily
introduced into the gingival sulcus without disturbing the adjacent gingival tissue. For
the same reason, they can easily be negotiated between teeth and the line angles of teeth.
It is especially useful in clinically healthy mouths where the gingiva is more closely
adapted to the teeth. By using this method we were able to consistently load higher
amounts of protein for electrophoretic analysis. An average of20 JlI was confidently
loaded each time.
The technique for collecting GCF with paper points was compared with the more
traditional method of using Perio Paper. Samples of GCF collected with
Perio Paper strips, as well as GCF collected using the paper point method described were
dot blotted and the average densities were calculated. Collection of GCF with
paper points yielded more consistent and significantly higher concentrations (3-6 fold)
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of recovered salivary proteins. These results indicate that the proteins could be
recovered more efficiently and reliably from the clipped paper point tips than by the
traditional Perio Paper method.
The collection of GCF is technique sensitive. The amount of GCF obtainable
from healthy gingival sulci is extremely small. It is necessary to collect enough GCF in
order to reasonably quantify the protein composition. Paper strips and glass capillary
tubes are the most common methods to collect GCF. However, the insertion of these
relatively large and inflexible objects into the gingival sulcus may cause mechanical
irritation and create an inflammatory response. A local inflammatory response will more
than likely alter the protein composition of the GCF and render any quantification
techniques useless. Once the GCF is collected on the paper strips it must be thoroughly
extracted and suspended in a buffer solution for analysis.
A commercially available Perio-Paper® strip commonly used to collect GCF
measures 2mm X 2mm. The large strips can cause problems in the collection of GCF
since they are not easily guided into the sulci of teeth and around the line angles where
again GCF is present. GCF absorbs into the large surface area ofPerio-Paper® and is
difficult to displace with a buffer solution. The Perio-Paper strip also absorbs much of
the buffer solution during storage and ultimately requires a greater volume of the buffer,
which decreases the final concentration of proteins in the sample. Recovery of the GCF
was relatively easy when a paper point is used. When the GCF was collected the paper
point was immediately cut above the point of 'wetting'. This prevents the GCF from
further absorbing in to the remaining portion of the paper point. The 'wetted' portion of
the paper point is more saturated with GCF since it absorbs less sample buffer solution
during storage. The technique used to collect is simple and easy to learn and is sliil1lar to
that of collection with Perio- Paper®. Collection ofGCF with glass capillary tubes also
presents problems since they are extremely technique sensitive and it takes some time to
learn the technique. The glass tubes are not flexible and can easily cause mechanical
irritation to the gingival sulcus. The tubes are also a source of anxiety as they appear
sharp and needle-like. In contrast, paper points present a minimal threat to children and
they can be invited to inspect and visualize the flexible piece of paper.
The development of a new collection and analytical technique provided the
opportunity to successfully study the molecular composition of GCF and calculate the
concentration of specific proteins. In both children and adults different protein patterns
were seen in GCF compared to those of whole saliva. These data indicate that GCF and
saliva constitute separate compartments with distinct protein compositions.
It was determined that total banding patterns were individually unique. While a
general pattern of previously identified major proteins was seen in all subjects tested, a
pleomorphy of discrete bands made a distinct individual profile. If these findings are
substantiated by further studies, then a number of potential applications can be
envisioned. For example, a unique individual secretory protein profile could serve as an
alternative or additional identification instrument to finger printing and may have
application in forensics.
Analyses of general protein profiles and comparison with specific components,
e.g. total proteins vs. cARP, may provide a means for measuring physiological responses
(e.g. mechanical stress or inflammation). Developing a clinical device may eventually be
useful for applications in diagnosis.
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Previous studies (~1ednieks ct aI, 1991, 1994) ha've shovvTI that the lc~vel o·f cARP
rises in acutely stre-ssful situations and falls below normal in chronic stress. There are no
objectiv~eways to evaluate tIle stress level of a cllild. TllOUgll il1ultiple scales are
available for indicating the behav~iorof a child, the~y are all subjecti\'~e. If a child coming
to the dental clinic is anxious, it w~ould be extremel:r useful for a pro'vider to kno",~ the
stress lC'vcl ofajuvcnilc patient objcctivrcly, to dctcnninc the extent of treatment which
can be accoIllplislled ill tllat visit. If a cllair-side biocilelllical test is 111ade available whicll
can instantly determine the level of cARP in a patient, it may serve as a tool to
accomplish treatment in a more humane and efficient manner.
Alternatively, if the level of cARP, which has a constant ratio to total protein in
nOfIllal subject, differs, tilell tllese cllallges tllay Sigtlify preSetlt or potelltial disease.
Such predictive instruments, on a nlolecular level, are not presently available. The
development of biochemical tests for diagnosis of potential susceptibility to oral or
systemic diseases, especiallyr in children, may have future applications.
FIGURE LEGENDS
Fig 1 Diagram of collection method used for GCF:
The panel on the left shows the introduction of a paper point into the gingival
crevice of a tooth. In the middle panel the wetted area is shown. The paper point was cut
just above the wetted area and transferred to the plastic tube (shown in the right panel),
which contains the sample buffer.
Fig 2 Developing a standard curve:
Protein concentrations were determined by developing a standard curve using
increasing concentrations ofbovine serum albumin (BSA). The Ponceau S stained dot
blot is shown below, and the corresponding optical densities vs the BSA concentrations
are plotted in the graph.
Fig 3 Dot blots on nitrocellulose membrane:
Shown here arel.5 JlI dot blots on a nitrocellulose membrane with various
salivary samples stained with Ponceau S red dye. Panel A shows the membrane as
prepared for densitometric analysis of total protein content in saliva. Samples 1-13
represent 13 salivary samples and samples 14 and 15 are BSA and a-amylase,
respectively. Panel B shows the same nitrocellulose membrane after immunoblotting for
cARP. Samples 14 and 15 are not recognized by the antibody.
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Fig 4 Comparison of staining methods:
Comparison of protein banding patterns on wet polyacrylamide gels stained with
Coomassie blue dye and on nitrocellulose paper stained with Ponceau S red dye. Panel A
shows an acrylamide gel stained with Coomassie blue dye and dried for scanning. Panel
B shows a transblot onto nitrocellulose paper of an identical sample stained with Ponceau
S red dye. Panel C shows densitometric Peak displays of the respective banding patterns.
The ordinate in panels A and B, and the abscissa in panel C, shows relative molecular
size in kilo Daltons (kD). There are fewer signals in the banding pattern with the Ponceau
S red dye~ nevertheless, all major peaks are visualized. Panels A and B are displayed in
pseudocolor to provide a visual comparison.
Fig 5 Total protein concentration of saliva (samples 1-25):
Graphical representation of total protein concentration of saliva in 25 children is
shown. The samples are shown on the X-axis and the density of total proteins is
presented on the Y-axis in arbitrary units. The values have a range ofO.2-2.81(arbitrary
units).
Fig 6 Total protein concentration of saliva (samples 26-49):
Graphical representation of total protein concentration of saliva in the next 24
children's samples is shown. The sample numbers are shown on the X-axis and the
density of total proteins is on the Y-axis, in arbitrary units. The values have a range of
O. 14-1.1(arbitrary units).
40
Fig 7 Total protein concentration of GCF:
Graphical representation of total protein concentration ofGCF in 25 children's
samples is shown. The sample numbers are shown on the X-axis and the density of total
proteins is on the Y-axis, in arbitrary units. The values have a range of 0.24-1.82
(arbitrary units).
Fig 8 Mean values of saliva and GCF:
Graphical representation of the mean values ofboth saliva (n=49) and GCF
(n==25) is shown here. The Y-axis shows the density in arbitrary units. The mean values
are 0.885 and 0.636, respectively. The standard deviation for salivary samples is 0.61 and
that for GCF is 0.37. All values shown are arbitrary.
Fig 9 Total protein concentration of saliva in 28 samples:
The total concentration of proteins is shown in the graph for 28 samples of
children's saliva. The X-axis shows the sample number and the Y-axis the density in
arbitrary units. The concentration of proteins in each individual is varied and unique.
Fig 10 Concentration of cARP in saliva of 28 samples:
The concentration ofcARP in the same 28 samples is shown in the form of a
graph. The X-axis shows the sample number and the Y-axis the density in arbitrary units.
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Fig 11 Mean values of cARP and total proteins for 28 samples:
Graphical representation of the mean values of both the total protein and cARP
concentrations in whole saliva is shown. The Y-axis shows the average density in
arbitrary units. The range for total protein is 0.46-2.62 and that of cARP is 0.010-0.48.
Protein lanes in the graph (blue) represent the concentration total proteins and cARP
lanes in the graph (red) represent the concentration ofcARP.
Fig 12 Comparison of cARP/total protein in saliva:
The comparison of cARP to total proteins present in the salivary samples of the
28 children is shown here. The X-axis shows the sample number and the Y-axis the
density in arbitrary units. Light gray bars represents the concentration total proteins and
dark gray bars, the concentration of cARP. Though the concentration of cARP differs in
each individual the percentage of cARP to total protein falls within the same range
Fig 13 Total protein concentration of salivary samples in male subjects:
Graphical representation of total protein concentration of saliva in 22 male
children's samples is shown. The sample numbers are shown on the X-axis and the
density of total proteins is on the Y-axis, in arbitrary llnits. The values have a range of
0.24-2.62 (arbitrary units).
Fig 14 Total protein concentration of salivary samples in female subjects:
Graphical representation of total protein concentration of saliva in 27 female
children's samples is shown. The samples are shown on the X-axis and the density of
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total proteins is presented on the Y-axis in arbitrary units. The values have a range of
0.19-2.69 (arbitrary units).
Fig 15 Mean values of salivary samples of male and female subjects:
Graphical representation of the mean values of salivary samples in male (n==22)
and female (n==27) children is shown here. The Y-axis shows the average density in
arbitrary units. The mean values are 1.017 and 0.792, respectively. The standard
deviation for male salivary samples is 0.662 and that for females is 0.57. All values
shown are in arbitrary units.
Fig 16 Total protein concentration of salivary samples in Caucasian children:
Graphical representation of total protein concentration of saliva in 23 Caucasian
children with European background (EC) samples is shown. The sample numbers are
shown on the X-axis and the density of total proteins is on the Y-axis, in arbitrary units.
The values have a range of 0.2-2.69 (arbitrary units).
Fig 17 Total protein concentration of salivary samples in Hispanic children:
Graphical representation of total protein concentration of saliva in 15
Hispanic/Latino (HIL) children's samples is shown. The sample numbers are shown on
the X-axis and the density of total proteins is on the Y-axis, in arbitrary units. The values
have a range of O. 14-1. 11 (arbitrary units).
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Fig 18 Total protein concentration of salivary samples in African American children:
Graphical representation of total protein concentration of saliva in 11
African American children's samples is shown. The sample numbers are shown on the X-
axis and the density of total proteins is on the Y-axis, in arbitrary units. The values have a
range of0.19-1.11 (arbitrary units).
Fig 19 Mean values of salivary samples ofEC, H/L and AA children:
Graphical representation of the mean values of salivary samples in European
Caucasians (EC}, Hispanics (H/L) and African Americans (AA) are shown. The n values
are 23, 15 and 11, respectively. The Y-axis shows the average density in arbitrary units.
The mean values are 1.15,0.681 and 0.559, respectively. The standard deviation for EC
salivary samples is 0.755, HIL is 0.33, and that for AA is 0.30 in arbitrary units. The
difference between EC and the other two groups is statistically significant (p < 0.05).
Fig 20 Total protein concentration of saliva in children in an age group of 6-9 years:
Graphical representation of total protein concentration of saliva in 29 children in
an age group of 6-9 years is shown. The sample numbers are shown on the X-axis and
the density of total proteins is on the Y-axis, in arbitrary units. The values have a range of
0.16-2.69 (arbitrary units).
Fig 21 Total protein concentration of saliva in children in an age group of 10-15 years:
Graphical representation of total protein concentration of saliva in 20 children in
an age group of 10-15 years is shown. The sample numbers are shown on the X-axis and
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the density of total proteins is on the Y-axis, in arbitrary units. The values have a range of
0.2-2.62 (arbitrary units).
Fig 22 Mean values of salivary samples for 2 different age groups:
Graphical representation of the mean values of salivary samples in two different
age groups, viz 6-9 and 10-15, are shown. The n values are 20 and 29, respectively. The
Y-axis shows the average density in arbitrary units. The mean values are 0.762 and 0.995,
respectively. The standard deviation for the 6-9 age group salivary samples is 0.537 and
that for the 10-15 age group is 0.698 in arbitrary units. There is no significant difference
between the two groups (p > 0.05).
Fig 23 Protein banding patterns and Western blotting of children's saliva:
Panel A shows the PAGE protein banding patterns after transblotting onto a
nitrocellulose membrane and staining with Ponceau S red dye. The first four lanes are
various standards purchased commercially. Lane M represents the Rainbow standard.
Lanes number one and two show RI (Sigma Chemical Company) and RII (Sigma
Chemical Company), respectively. Lane three was a preparation of a-amylase purchased
from a commercial vendor (Sigma Chemical Corporation). Lanes 4-8 represent the
banding patterns of five children's whole saliva samples. In Panel B the same tnembrane
is seen after immunoblotting for cARP. Lanes 4-8 show the presence ofRI only in all
of the saliva samples. This differs from that of adult samples where RII was more
commonly seen.
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Fig 24 Densitometric analysis of total proteins and cARP in children's saliva:
Panel A shows the densitometric analysis of the protein banding patterns from Fig
23. Note the consistent presence of a peak at the 90 kD areas in all five samples. Panel B
shows the densitometric analysis of the same samples after immunoblotting for cARP.
There is a consistent presence of a protein of the relative mobility ofRI. Note that the
values on the X-axis vary for panels A and B.
Fig 25 Protein banding pattern and Western blotting of children's whole saliva and GCF:
Shown here are the protein banding pattern and Western blot of children's whole
saliva (lanes 1,3,5,7 and 9) and GCF (lanes 2,4,6,8 and 10). Relative molecular size, kD,
is shown by bands from a commercial protein standard marker (lanes Ml and M2)
solution on the polyacrylamide gel electrophoretic pattern (PAGE), shown in panel A.
Lanes 1-10 represent alternating whole saliva and GCF sanlples of 5 children. Panel B
shows the Western blot (WB) of the nitrocellulose membrane from panel A, with
antibody to RII/cARP. Predominantly RI is present in saliva, while both RI and RII are
present in GCF.
Fig 26 Densitometric analysis of children's whole saliva and GCF:
Shown here is the densitometric analysis of the PAGE patterns in panel A of Fig
25. It shows various protein peaks represented graphically and distinctions between
whole saliva and GCF. Peaks seen in each saliva sample consistent with the relative
mobility of a-amylase are generally absent in GCF.
46
Fig 27 Western blotting and densitometry of proteins shown in Fig 25:
Immunoblotting of the above membrane reveals the consistent presence ofR! in
all children's saliva samples (Lanes 1,3,5,7 and 9), whereas both RI and RII were seen in
GCF samples (Lanes 2,4,6,8 and 10). Densitometric analyses performed on all 10
samples are shown.
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Table 1 Total protein concentration in saliva and GCF
Group
Saliva
GCF
Mean
0.887
0.636
SD
0.610
0.337
n
49
25
The difference in protein concentration of whole saliva and gingival crevicular
fluid (GCF) is presented. There is a 10 fold dilution factor for GCF and hence the
value ofGCF is approximately 10 times higher than what is shown here.
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Table 2 Total protein concentration based on gender
Group
Males
Females
Mean
1.017
0.792
SD
0.662
0.574
n
22
27
The difference in concentration of salivary protein in whole saliva
between males and females was determined. The difference was not
statistically significant
76
Table 3 Total protein concentration in children's saliva based on ethnicity
Subject group
EC
H
AA
Mean
1.15
0.681
0.559
SD
0.755
0.330
0.302
n
23
15
11
The children are divided into European background Caucasians (EC), Hispanic
(H) and African Americans (AA). The sample means, the standard deviations
(SD) and the number of samples (n) are shown in columns 1-3 respectively. The
difference in concentration of salivary proteins between EC and that ofR and AA
was statistically significant
77
Table 4 Total protein concentration in two different age groups
Age group
6-9 years
10-15 years
Mean
0.762
0.995
SD
0.537
0.698
n
29
20
The salivary samples were divided into two age groups within the mixed
dentition. The difference in concentration of salivary protein between the
two age group (6-9 and 10-15) is not statistically significant
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Type of Project:
New
X Continuation*
Duplicate Submission*
X Modification/Addendum
*
Training/Center
(·Include: Title/IRB#/ Last ApprovalDate:_Secretory Protein Expression in Human Saliva/98-
177/ 1/12/99 )
************************************************************************************
I. Project Location:
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X Uconn Health Center
VA Medical Center
Other: _
D. Cooperating
Institutions:
ID. Type of Human Subjects to be Used:
X Children/Adolescents
X Males
X Females
Inpatients
X Outpatients
Pregnant Women
Mentally/Physically
Handicapped
Fetuses
Abortuses
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08-80
IV. Project Involves the Use of An Investigational New Drug:
X No
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VI. Project involves the Use of Radiation or Radioisotopes:
X No
(If yes, inform the Radiation Safety Office prior to IRB submission. Approval from the
Committee of Research Safety and Environmental Health (CRSEH) may be necessary.)
VII. Signatures: Applicant (and Faculty Sponsor if Applicant is Non-Faculty)
Signature.. 'f:' · - 1..!~ .
Date 3 ..[.1. .g.~ .
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This abstract should contain a clear and succinct description of the long-term objectives and specific aims
of this project with specific reference to its health relatedness. It should also include an accurate
description of the experimental design and methods of achieving these goals. This abstract is meant to
serve as a complete description of the proposed study. DO NOT EXCEED THE SPACE PROVIDED.
The purpose of this study is to determine the expression of secretory proteins in two types of oral
fluid: whole saliva and in gingival crevicular fluid. Individual protein patterns of each person are unique
and may be used for identification purposes. Additionally elevation or decrease below basal levels of
specific proteins may be an index of specific disorders or may serve as indices of susceptibility to some
disorder.
Samples of saliva will be collected from normal, healthy individuals by allowing a small amount to
flow into a sterile tube or by touching a sterile paper strip to the area between the canine teeth and the
gingiva. All procedures will be carried out using full infection control precautions and following UCHC and
NIH guidelines.
Proteins which will be studied include secretory proteins such as salivary enzymes such as alpha
amylase, salivary immunoglobulins such as IgA, and cellular regulatory proteins such as cyclic AMP
receptor proteins (cARP). Standard methods for polyacrylamide electrophoresis and Western Blotting will
be employed.
Collection of saliva is a noninvasive procedure that poses no danger to either the subject or the
investigator, takes very little time and can be carried out either in the clinic or the laboratory. This
investigation is intended to develop a potentially useful system for the identification of an individual as
well as detecting existing or potential disorders, most likely those related to stress.
***************************************************************************
In the space below, provide a flow diagram or outline of the experimental design of the investigation
focusing on those aspects that involve human subjects and emphasizing the specific time sequence of the
procedures to be performed.
1) Subject selection.. Only healthy individuals able to understand the protocol as described on the
Consent Form will be asked if they would be interested in participating in this study.
2) Sample collection. Two types of oral fluid will be collected: whole saliva from the oral cavity will be
collected by asking the subject to allow a small quantity (1-2 ml) to flow into a sterile tube. Gingival
crevicular fluid (GCF) will be collected by touching a sterile paper strip to the crevice between a tooth and
the gingiva. The sample size obtained from this area is approximately 1 - 2 IJ:W:m liters. The saliva
smples will be treated with a preservative solution and stored at -40°C until use.
3) Electrophoresis: The collected whole saliva will be heated with a denaturing solution and the proteins
will be separated by polyacrylamide gel electrophoresis (pAGE). The proteins will then be transferred
from the acrylamide gel to a nitrocellulose membrane by electroblotting and stained to visualize the total
protein pattern. This pattern will be recorded by a digitized scanning process and stored as a computer
file.
4) Western Blotting: To localize specific proteins on the general protein patterns, the membranes will be
incubated with antibody solutions specific for an individual protein and compared to controls. These blots
can be run on duplicate gels and several individual protein patterns can be determined.
5) Densitometry: Quantification of the total proteins determined by PAGE will be carried out by a
densitometric analysis of the banding patterns. Determination of the specific proteins will be done by
densitometric analysis of the Western blotting bands. The quantification will be normalized by calculating
ratios of amounts of each specific protein to the amount of the total proteins.
6) Data Analysis and Applications. By carrying out these analyses an array of total protein patterns can
be established for each individual tested. Secondly, the expression of specific proteins can be determined
and compared to an established baseline. For example, a ratio of approximately 0.03 has been found for
cARP to total proteins. In the case of persistent environmental stress this ratio drops significantly
whereas under short-term acute stress, the ratio rises and then returns to normal
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***************************************************************************
1. List specific eligibility requirements for subjects, including those criteria which would
exclude otherwise acceptable subjects.
Inclusion:----------------............... Exclusion:
a. in good health; not on medication a. physical or mental disorders
b. able to understand the protocol b..not able to understand the protocol
c. participate without compensation c. require compensation
d. d. _
2. a.) How will subjects be recruited? b.) Explain process of obtaining consent.
a) Patients at UCHC dental clinics and UCHC staff and students will be approached and asked if they
would be willing to participate in a study. The study would then be explained and the sample collection
would be described. b) Consent will be obtained following standard procedures in use at UCHC The
subjects will be informed that there will be no negative consequences if they do not wish to participate in
the study. The subjects will be informed that they can stop participating at any time and that this will
have no effect on their treatment, their academic progress or their work situation.
3. List all procedures (both experimental and non·experimental) to be performed on human subjects. Also
list alternate procedures available to the subject.
Procedures:
none
Experimental:
None
Non.experimental:
None
Alternate procedures/treatments:
none
***************************************************************************
4. State the potential risks (e.g. psychological, social, legal, drug toxicities) associated with the proposed
procedures.
The research to be conducted poses no risk to the patient.
5. Describe procedures to protect against or minimize potential risks and to assure confidentiality.
Potential Risks:
none
Confidentiality: Individual samples are identified only by a coded number
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6. What benefit, if any, is to be gained by the subject? In the event of monetary gain, include all payment
arrangements, including reimbursement of expenses, free medication, etc.
None
7. Describe any costs related to the research procedures that are over and above those incurred by
standard treatment, and indicate who will be responsible for them.
none
B. What new information may arise from this work?
Knowledge of the expression of various proteins in saliva
INFORMED CONSENT CHECKLIST
Informed Consent is a representation of the interaction between the subject and the researcher. The
checklist covers the required elements of informed consent, and must be completed by the investigator as
part of this application. If a submission contains an informed consent statement which does not address
each of the elements, it will be returned to the investigator for revision, possibly resulting in a delay of the
review process. Assistance in preparation of the informed consent form is available by calling the IRB
Office, 679-2142. A sample consent form is available.
IRB - Informed Consent Checklist
_X_I. Use wording understandable to the subject population, and exclude any statements which may
be considered coercive (unduly encourage subjects to participate).
_X_2. At the beginning of the consent form give an explanation of the procedures to be followed
including: a) purpose of research; b) procedures which are experimental; c) expected duration of the
subject's participation.
_N/A_3. Description of the risks, discomforts, and side effects.
_X_4. Description of the safeguards to be used to protect the subject.
_N/A_5. If project involves experimental therapy, discuss alternate treatment procedures available (i.e.
the subject has to know what is available to himlher if the choice is made not to participate).
_N/A_6. Description of benefits to be expected.
_X_7. An offer to answer any inquiries concerning the procedures.
_X_B. Tell subjects that participation is voluntary and they may refuse to participate.
_X_9. State that the subjects may withdraw, or be withdrawn from the study at any time without
jeopardizing present or future care. describe anticipated circumstances under which the subject's
participation may be terminated by the investigator without regard to the subject's consents.
~10. State the terms of subject compensation for participation, if any.
_N/A_l1. State clearly what costs the subject will incur by participating in the study, and what will be
paid for as part of the study.
_X_12. State that every effort will be made to maintain confidentiality.
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a. In research involving FDA regulated products, the consent form must contain a statement that the FDA
and the drug company may inspect the subject's research and medical records. b. For VA studies involving
an INDIIDE the consent form must have the following language verbatim *1 have been informed that
because this study involves articles regulated by the FDA (Food and Drug Administration), the FDA may
choose to inspect records (including my medical records) identifying me as a subject in this investigation.*
_X_13. a) The name and telephone number of the principal investigator or other
responsible individual who can to be contacted if the subject experiences problems or an
adverse effect during the research study. b) An explanation of whom to contact for answers to
questions about the research. c) For questions about the rights as a research subject use the following
language: "If you have questions regarding your rights as a research subject you may contact an IRB
Representative at 860/679-3054".
INCLUDE #14-17, if appropriate
_N/A_14. A statement that the particular treatment or procedure may involve currently unforeseeable
risks to the subject.
_N/A_15. The procedures for orderly termination of participation by the subject (i.e. removal of a device or
discontinuation of study drug).
_N/A_16. A statement that significant new findings that arise during the course of research, and which
may relate to the subject's willingness to continue participation, will be provided to the subject.
_N/A_17. The approximate number of subjects involved in the study at this facility compared to overall
subject population.
_X_18. Include a statement of consent to participate in the study.
_X_19. Include a statement that the subject has received a copy of the consent form.
_X_20. Inclusion of the appropriate policy statement regarding compensation in the
event of a research related injury for projects involving more than minimal risk:
a. For Projects Conducted at UConn Health Center include the following:
The University of Connecticut Health Center (UCHC) does not provide insurance
coverage to compensate me if I am injured during this research. However, I may still
be eligible for compensation. If I am injured, I can file a claim against the state of
Connecticut seeking compensation. For a description of this process, or available
compensation options, I may contact a representative of the UCHC Institutional Review board (lRB) at
860/679-3054
The UCHC does not offer free care. However, treatment for a research related
injury may be obtained at UCHC for the usual fee.
If I need additional information, I may contact the IRB at 860/679-3054 who can review the matter with
me, identify the resources that may be available, and provide me with further
information as to how to proceed.
b. For VA projects include the following:
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If you are physically injured as a result of taking part in this study, all necessary and appropriate care
will be provided if you are eligible for medical care as a veteran. In the event of such injury, compensation
mayor may not be payable under federal law. Further information regarding eligibility for medical care
and compensation under federal law in the event of injury, may be obtained from the Chief of Medical
Administration Service at the Newington, VA, telephone number 666-6951.
_X_21. Include a signature and date line for each of the following:
Subject
Investigator or Person Obtaining consent
Witness (must be someone other than individual obtaining consent).
_X__22. For Projects Involving Subjects Under the Age of 18 Years:
a. If the subject is 12 years of age or older, the subject signs the consent form and a parent or guardian
also signs the consent form. No assent statement is required.
b. If the subject is between 7-12 years of age, and the study is a therapeutic trial*:
the subject sign nothing; and the parent which must be included at the end of the consent form after
the signature lines.
I am satisfied that Dr. has discussed these procedures with my child in a manner and to an
extent that is appropriate for hislher capacity to understand at the present time. My child has been
informed of the procedures that will be performed, the reason for such treatment, and the associated risks.
In addition, all of the alternative procedures and the voluntary nature of their participation have been
described.
As the parent (or guardian) of (subject's name), I am signing this
consent form and authorizing the above procedures to be performed because in my judgment, my child is
not mature enough to fully understand the complexities of the procedures involved with hislher treatment.
(Include signature and date lines for Parent, Person Obtaining consent, and Witness).
OR
The study is not therapeutic trial*:
the parent or guardian signs the consent form; and the subject signs the following assent statement which
must be included at the end of the consent form after the signature lines.
My (include appropriate person, doctor, dentist, psychologist, researcher, etc.) and parents have talked to
me about being part of a study of (explain study in child-appropriate language). I understand the reason
for the study and why I am being asked to take part in it. I have been told that as a subject in the study I
will have the following performed: (list procedures to be followed in child-appropriate language--the
statement need not be as detailed as information provided to an adult). I understand that these
procedures may cause (list potential harmful effects in child-appropriate language). I know that I an ask
questions about this study at any time. I also know that I can decide not to be in this study, or after
entering the study I can decide that I want to be taken out of it.
Whatever I decide to do, I know my (include appropriate person as above) will not be angry with me and
continue to treat me as hislher patient.
(Include signature and date lines for subject, Person Obtaining Consent, and Witness)
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c. If the subject is less than 7 years of age, the parent or guardian signs the consent form, the subject
signs nothing. No assent statement is required.
*Note: If you have any questions regarding what qualifies as a therapeutic or
non-therapeutic trial, please call the IRB Office
Revised 10/98
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CONSENT FORM
Study Title:
Principal Investigator:
"Secretory Protein Expression in Human Saliva"
Dr. Arthur R. Hand
Department of Pediatric Dentistry
(860) 679-4085
Human Subjects Oversight Committee Approval: IRB# 98-177
Description and Purpose of the Study:
In this study enzymes and other proteins of human oral fluid (saliva from the mouth) will
be measured and identified so that changes that take place during human development and
growth can be identified.
You will be asked to make a donation of a small amount (about a teaspoon full) of saliva
and a small amount (less than a drop) of fluid from the crevice between the gums and the teeth.
These procedures do not cause any pain or do any harm. The total time will not be more than
10 minutes. The length of this study will be approximately one year.
The samples will be collected by:
1) allowing saliva to run from the mouth into a small sterile cup
2) by touching an absorbent sterile strip to the inside of the cheek or under the tongue
3) by touching a narrow sterile strip of absorbent material to the crevice between the teeth and
gums.
To protect your privacy, your name will not be used. The samples will be identified by a number
code. Your participation or withdrawal from the study will not affect your treatment or medical
outcome. You will not receive payment or other benefits from volunteering. It is hoped that the
results of this study may help in diagnosis or treatment of some diseases.
If you agree to participate and have understood this information, please sign this statement:
"I have been informed of the nature of this study and understand that I can stop
participating at any time. II
Signature of subject or parent/guardian
Signature of doctor
Signature of witness
date
date
date
APPROVED ON
ul,nl--.~r
The University of Connecticut Health Center does not provide free care. If there are any
questions regarding this protocol, Ms. Joanne R.Lamothe, Executive Secretary of the IRS, may ~ RD
be contacted at (860) 679-3054 or bye-mail, lamothe@nso.uchc.edu ~ v~o
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CONSENT FORM cont'd.
Non-Therapeutic Study Consent Form For Subjects Between Ages 7-12 Years Old.
Dr. and my parents have talked to me about being in this study.
I will give a small sample of my saliva for the doctor to use for laboratory experiments. I
understand that this will not cause me any pain or harm and that I can ask questions to the
doctor at any time. I also know that I can decide not to be in this study at any time and that
Dr. will not be angry with me and will continue to treat me as
his/her patient.
Signature of subject
Signature of doctor
Signature of witness
date
date
date
For Projects at the University of Connecticut Health Center Involving More Than Minimal Risk:
(This Project Poses No Risk)
The University of Connecticut Health Center (UCHC) does not provide insurance coverage to
compensate me if I am injured during this research. However, I may still be eligible for
compensation. If I am injured, I can file a claim against the State of Connecticut seeking
compensation. For a description of this process, or available compensation options, I may
contact Ms. Joanne R.Lamothe, Executive Secretary of the IRS at the UCHC, at (860) 679-3054
or bye-mail, lamothe@nso.uchc.edu.
The UCHC does not provide free care. However, treatment for a research-related injury may be
obtained at UCHC for the usual fee.
If I need additional information, I may contact Ms. Joanne R.Lamothe, Executive Secretary of
the IRS at the UCHC, at (860) 679-3054 or bye-mail, lamothe@nso.uchc.edu. The Executive
Secretary can review that matter with me, identify the resources that may be available, and
provide me with further information as to how to proceed.
APPROVED ON
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Office of Clinical Research
Institutional Review Board (IRB)
263 Farmington Avenue MC-2806
Farmington, CT 06030-2806
860-679-3054 (Phone)
860-679-1856 (Fax)
Principal Investigator:
Co-Investigators:
Reference Number:
Progress Report Due:
Type of Review:
IRB Meeting Date:
Dr. Arthur Hand
Pediatric Dentistry 1610
Maija Mednieks
98-177
2/28/01
Modification/Continuation Expedited
4/17/00
Proposal: Secretory Protein Expression in Human Saliva
(Sponsor: )
Approved for continuation on 4/17/2000. Study determined to qualify for expedited review under the revised
Expedited Federal Regulation (rev. 11/98) Title 45 Code of Federal Regulation Part 46, section 46.110(3).
Please note that since this study had lapsed on December 31, 1999, you are not authorized to enroll any new
subjects while a study is not approved. The IRB OUice requests that future continuations be submitted in a
timely fashion. The PI is required to use the attached IRB approved consent form valid through 4/30/2001.
• IRB approval is valid for one additional year through 4/30/01.
With approval of a proposal, the committee requests that should any untoward effects occur, the committee
be informed immediately. In addition, should there be any modifications or changes contemplated, it is
necessary that the committee be informed in writing, for review and approval prior to their inception.
It is the committees' understanding that this proposal will be terminated as 4/30/01 unless the investigator
notifies the committee that the study will be continued.
cc: Department Chair, Pediatric Dentistry
OASP, Me 5355
